KR101719008B1 - 약물 투여용 조성물 - Google Patents
약물 투여용 조성물 Download PDFInfo
- Publication number
- KR101719008B1 KR101719008B1 KR1020117017361A KR20117017361A KR101719008B1 KR 101719008 B1 KR101719008 B1 KR 101719008B1 KR 1020117017361 A KR1020117017361 A KR 1020117017361A KR 20117017361 A KR20117017361 A KR 20117017361A KR 101719008 B1 KR101719008 B1 KR 101719008B1
- Authority
- KR
- South Korea
- Prior art keywords
- delete delete
- drug
- alkyl
- administration
- pharmaceutical composition
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/341,696 US8268791B2 (en) | 2004-08-25 | 2008-12-22 | Alkylglycoside compositions for drug administration |
US12/341,696 | 2008-12-22 | ||
PCT/US2009/069326 WO2010075465A1 (fr) | 2008-12-22 | 2009-12-22 | Compositions pour administration de médicaments |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20110099049A KR20110099049A (ko) | 2011-09-05 |
KR101719008B1 true KR101719008B1 (ko) | 2017-03-22 |
Family
ID=42288137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020117017361A KR101719008B1 (ko) | 2008-12-22 | 2009-12-22 | 약물 투여용 조성물 |
Country Status (15)
Country | Link |
---|---|
US (1) | US8268791B2 (fr) |
EP (1) | EP2381773B1 (fr) |
JP (2) | JP5752048B2 (fr) |
KR (1) | KR101719008B1 (fr) |
CN (1) | CN102325450B (fr) |
AU (1) | AU2009329952B2 (fr) |
BR (1) | BRPI0923403B1 (fr) |
CA (1) | CA2748268C (fr) |
DK (1) | DK2381773T3 (fr) |
ES (1) | ES2667248T3 (fr) |
HK (1) | HK1164059A1 (fr) |
MX (1) | MX356271B (fr) |
NZ (1) | NZ593782A (fr) |
RU (1) | RU2554814C2 (fr) |
WO (1) | WO2010075465A1 (fr) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
US9895444B2 (en) | 2004-08-25 | 2018-02-20 | Aegis Therapeutics, Llc | Compositions for drug administration |
WO2006083761A2 (fr) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solutions de solvant/polymere utilisees comme vehicules de suspension |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
MX2008014870A (es) | 2006-05-30 | 2009-02-12 | Intarcia Therapeutics Inc | Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas. |
ES2422864T3 (es) | 2006-08-09 | 2013-09-16 | Intarcia Therapeutics, Inc | Sistemas de liberación osmótica y unidades de pistón |
US8653066B2 (en) | 2006-10-09 | 2014-02-18 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
AU2008244523B2 (en) | 2007-04-23 | 2012-02-16 | Intarcia Therapeutics, Inc. | Suspension formulations of insulinotropic peptides and uses thereof |
US8530463B2 (en) * | 2007-05-07 | 2013-09-10 | Hale Biopharma Ventures Llc | Multimodal particulate formulations |
JP2010526822A (ja) * | 2007-05-07 | 2010-08-05 | クエスター ファーマシューティカルズ,インク. | ベンゾジアゼピン類の経鼻投与 |
CA3066426A1 (fr) | 2008-01-09 | 2009-07-16 | Charleston Laboratories, Inc. | Compositions pharmaceutiques renfermant un antiemetique et un analgesique opioide |
US8343140B2 (en) | 2008-02-13 | 2013-01-01 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
US20090258865A1 (en) * | 2008-03-28 | 2009-10-15 | Hale Biopharma Ventures, Llc | Administration of benzodiazepine compositions |
EP2451274B1 (fr) | 2009-07-08 | 2017-10-04 | Charleston Laboratories, Inc. | Compositions pharmaceutiques |
US9775819B2 (en) * | 2009-09-16 | 2017-10-03 | R.P. Scherer Technologies, Llc | Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin |
NZ599344A (en) * | 2009-09-25 | 2015-02-27 | Reddy’S Lab Ltd Dr | Formulations comprising triptan compounds |
RU2710372C2 (ru) * | 2009-09-25 | 2019-12-26 | Д-Р Редди'С Лабораторис Лтд. | Композиции, содержащие триптановые соединения |
US11337962B2 (en) | 2009-09-25 | 2022-05-24 | Upsher-Smith Laboratories, Llc | Formulations comprising triptan compounds |
ES2553862T3 (es) * | 2009-09-25 | 2015-12-14 | Dr. Reddy's Laboratories Ltd. | Formulaciones que comprenden compuestos de triptán |
EP3735944A1 (fr) * | 2009-09-28 | 2020-11-11 | Intarcia Therapeutics, Inc. | Établissement rapide et/ou arrêt rapide d'une administration constante substantielle de médicament |
US20120270778A1 (en) * | 2009-12-18 | 2012-10-25 | Aegis Therapeutics Llc | Compositions and Methods for Non-Invasive Treatment of Chronic Complications of Diabetes |
WO2011094632A1 (fr) * | 2010-01-29 | 2011-08-04 | The Uab Research Foundation | Procédé pour l'administration d'insuline et composition pharmaceutique de celle-ci |
US20150132344A1 (en) * | 2010-11-18 | 2015-05-14 | Universite De Montreal | Oral Leptin Formulations and Uses Thereof |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
ES2917973T3 (es) | 2011-06-14 | 2022-07-12 | Neurelis Inc | Administración de benzodiacepina |
EP2780029A4 (fr) * | 2011-11-18 | 2015-06-24 | Univ Montreal | Formulations orales de leptine et leurs utilisations |
SG10201605800UA (en) * | 2012-07-12 | 2016-09-29 | Mannkind Corp | Dry powder drug delivery system and methods |
WO2015032981A1 (fr) * | 2013-09-09 | 2015-03-12 | Lek Pharmaceuticals D.D. | Conjugués d'érythropoïétine présentant une biodisponibilité orale |
EP3052604B1 (fr) | 2013-09-30 | 2023-05-31 | Enza Biotech AB | Utilisation de tensioactifs à base d'alkylglycosides |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
EA034820B1 (ru) * | 2015-02-17 | 2020-03-25 | Эли Лилли Энд Компани | Порошковый состав для интраназального введения для лечения гипогликемии |
EP4278996A3 (fr) | 2015-06-03 | 2024-01-24 | i2o Therapeutics, Inc. | Systèmes de mise en place d'implant |
EP3316865A4 (fr) | 2015-07-02 | 2019-01-23 | Civitas Therapeutics, Inc. | Poudres contenant un triptan, à administrer par voie pulmonaire |
US20170119738A1 (en) * | 2015-10-28 | 2017-05-04 | Dr. Reddy's Laboratories, Ltd. | Pharmaceutical compositions for rizatriptan |
TWI745313B (zh) * | 2015-10-30 | 2021-11-11 | 日商帝人製藥股份有限公司 | 鼻黏膜投與用醫藥組成物 |
WO2017152130A1 (fr) | 2016-03-04 | 2017-09-08 | Charleston Laboratories, Inc. | Compositions pharmaceutiques |
AU2017268161B2 (en) | 2016-05-16 | 2020-03-12 | Intarcia Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
RU2767062C2 (ru) * | 2016-06-24 | 2022-03-16 | Опиант Фармасьютикалз, Инк. | Составы, устройства и способы для лечения алкогольной зависимости |
AU2017360910B2 (en) | 2016-11-18 | 2023-11-23 | Aegis Therapeutics, Llc | Compositions and methods for the treatment of opioid overdose |
CA3049034A1 (fr) | 2017-01-03 | 2018-07-12 | Intarcia Therapeutics, Inc. | Methodes comprenant l'administration continue d'un agoniste du recepteur glp-1 et la co-adminstration d'un medicament |
WO2020163620A1 (fr) * | 2019-02-06 | 2020-08-13 | Axsome Therapeutics, Inc. | Compositions pharmaceutiques comprenant du méloxicam |
MX2019008972A (es) * | 2017-02-09 | 2019-09-10 | Sekisui Chemical Co Ltd | Estructura de nucleo-envoltura, preparacion, medicina para aplicacion externa, agente de cinta y producto cosmetico. |
US20220096438A1 (en) | 2018-09-07 | 2022-03-31 | Upsher-Smith Laboratories, Llc | Methods of treating migraine |
EA202091615A1 (ru) | 2018-12-21 | 2021-03-05 | Аегис Терапьютикс, Ллс | Интраназальные составы на основе эпинефрина и способы лечения заболевания |
US20220249465A1 (en) * | 2019-05-31 | 2022-08-11 | Primo Pharmatech Llc | Unit dosage form for transmucosal drug delivery of an active pharmaceutical ingredient |
US12005077B1 (en) * | 2023-09-28 | 2024-06-11 | Terry Earl Brady | Broad-spectrum antimicrobial, biocompatible and preservative-free functionalized fullerenes ophthalmic solution with reactive oxygen species scavenging and advanced targeting, penetration, and hydration |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060045868A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
US20070059254A1 (en) | 2003-08-21 | 2007-03-15 | Transoral Pharmaceuticals, Inc. | Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US411210A (en) | 1889-09-17 | Water-wheel | ||
US3219656A (en) | 1963-08-12 | 1965-11-23 | Rohm & Haas | Alkylpolyalkoxyalkyl glucosides and process of preparation therefor |
US3547828A (en) | 1968-09-03 | 1970-12-15 | Rohm & Haas | Alkyl oligosaccharides and their mixtures with alkyl glucosides and alkanols |
US3839318A (en) | 1970-09-27 | 1974-10-01 | Rohm & Haas | Process for preparation of alkyl glucosides and alkyl oligosaccharides |
GB1355998A (en) | 1970-09-30 | 1974-06-12 | Unilever Ltd | Builders for detergent compositions |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4036228A (en) | 1975-09-11 | 1977-07-19 | Alza Corporation | Osmotic dispenser with gas generating means |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4130709A (en) | 1977-12-08 | 1978-12-19 | Eli Lilly And Company | Pleuromutilin glycoside derivatives |
JPS57128634A (en) | 1981-02-03 | 1982-08-10 | Eisai Co Ltd | Elastase-containing compound increasing absorption |
US4440675A (en) | 1981-08-18 | 1984-04-03 | Meloy Laboratories, Inc. | Human immune interferon |
AT382381B (de) | 1984-10-02 | 1987-02-25 | Oesterr Zuckerfab Evidenz | Verfahren zur herstellung neuer grenzfl|chenaktiver kohlenhydrat-derivate |
DE3444958A1 (de) | 1984-12-10 | 1986-06-12 | Henkel KGaA, 4000 Düsseldorf | Verwendung von alkylglykosiden als potenzierungsmittel in antiseptischen mitteln sowie desinfektions- und reinigungsmittel mit verstaerkter bakterizider wirkung |
DK17685D0 (da) | 1985-01-14 | 1985-01-14 | Hans Goeran Magnusson | Glycosidderivater |
US5192528A (en) | 1985-05-22 | 1993-03-09 | Liposome Technology, Inc. | Corticosteroid inhalation treatment method |
US5550220A (en) | 1987-05-13 | 1996-08-27 | Curtice-Burns, Inc. | Alkyl glycoside fatty acid polyester fat substitute food compositions and process to produce the same |
US4938931A (en) | 1987-05-26 | 1990-07-03 | Hoechst Celanese Corporation | Microporous membrane trickle bed reactor |
US4921838A (en) | 1987-06-16 | 1990-05-01 | Trustees Of Boston University | Angiogenic and blood perfusion inducing properties of amphiphilic compounds |
WO1990005535A1 (fr) | 1988-11-14 | 1990-05-31 | Otsuka Pharmaceutical Co., Ltd. | Preparation a base d'interferon pour administration nasale |
US5705363A (en) | 1989-03-02 | 1998-01-06 | The Women's Research Institute | Recombinant production of human interferon τ polypeptides and nucleic acids |
US5182258A (en) | 1989-03-20 | 1993-01-26 | Orbon Corporation | Systemic delivery of polypeptides through the eye |
US5122187A (en) | 1989-06-22 | 1992-06-16 | Xerox Corporation | Hot melt ink compositions |
US5198420A (en) | 1989-10-02 | 1993-03-30 | The General Hospital Corporation | Use of mullerian inhibiting substance and its agonists and antagonists in the treatment of respiratory distress syndrome |
US5369095A (en) | 1990-02-14 | 1994-11-29 | Alcon Laboratories, Inc. | Compositions and method comprising substituted glycosides as mucus membrane permeation enhancers |
US5252318A (en) | 1990-06-15 | 1993-10-12 | Allergan, Inc. | Reversible gelation compositions and methods of use |
WO1992000310A1 (fr) | 1990-06-27 | 1992-01-09 | Dainippon Ink & Chemicals, Inc. | Oligosaccharide alkyle et derive acetyle de celui-ci |
US5288707A (en) | 1990-08-13 | 1994-02-22 | Sandoz Ltd. | Borolysine peptidomimetics |
ES2095348T3 (es) | 1991-05-16 | 1997-02-16 | Kao Corp | Solucion acuosa de alquilglucosido estable contra la actividad microbiana. |
US5552534A (en) | 1991-08-22 | 1996-09-03 | The Trustees Of The University Of Pennsylvania | Non-Peptide peptidomimetics |
US5317010A (en) | 1991-10-10 | 1994-05-31 | Peter K. T. Pang | Parathyroid hormone analogues substituted at AA 25, 26, 27, and use in osteoporosis treatment |
US5236707A (en) | 1991-11-08 | 1993-08-17 | Dallas Biotherapeutics, Inc. | Stabilization of human interferon |
US5550251A (en) | 1991-12-12 | 1996-08-27 | The Trustees Of The University Of Pennsylvania | Alicyclic peptidomimetics |
US5308531A (en) | 1992-08-31 | 1994-05-03 | Henkel Corporation | Pine-oil containing hard surface cleaning composition |
WO1994005262A1 (fr) | 1992-09-10 | 1994-03-17 | F.H. Faulding & Co. Limited | Composition sous forme de matrice a liberation prolongee |
CZ286632B6 (cs) | 1992-09-29 | 2000-05-17 | Inhale Therapeutic Systems | Farmaceutický prostředek |
WO1994020116A1 (fr) | 1993-03-10 | 1994-09-15 | University Of Alabama Research Foundation | Amorces artificielles pour la synthese du glycogene |
US6794357B1 (en) | 1993-06-24 | 2004-09-21 | Astrazeneca Ab | Compositions for inhalation |
US5661130A (en) | 1993-06-24 | 1997-08-26 | The Uab Research Foundation | Absorption enhancers for drug administration |
US5510264A (en) | 1993-09-28 | 1996-04-23 | Insight Biotech Inc. | Antibodies which bind meningitis related homologous antigenic sequences |
CA2174324A1 (fr) | 1993-10-21 | 1995-04-27 | Katsuya Mukae | Composition administree par voie nasale et preparation contenant celle-ci |
US5576014A (en) | 1994-01-31 | 1996-11-19 | Yamanouchi Pharmaceutical Co., Ltd | Intrabuccally dissolving compressed moldings and production process thereof |
US5556940A (en) | 1994-06-20 | 1996-09-17 | National Research Council Of Canada | Parathyroid hormone analogues for the treatment of osteoporosis |
US5955425A (en) | 1996-08-02 | 1999-09-21 | National Research Council Of Canada | Parathyroid hormone analogues for the treatment of osteoporosis |
SE9404196D0 (sv) | 1994-12-02 | 1994-12-02 | Astra Ab | New antithrombotic formulation |
US6524557B1 (en) | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
SE9404468D0 (sv) | 1994-12-22 | 1994-12-22 | Astra Ab | Powder formulations |
EE9700138A (et) | 1994-12-22 | 1997-12-15 | Astra Aktiebolag | Aerosoolravimvormid |
US20030118594A1 (en) | 1995-06-07 | 2003-06-26 | Bishwajit Nag | Stable formulations of mhc-peptide complexes |
US6852690B1 (en) | 1995-08-22 | 2005-02-08 | Amylin Pharmaceuticals, Inc. | Method and composition for enhanced parenteral nutrition |
US5914332A (en) | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US6254854B1 (en) | 1996-05-24 | 2001-07-03 | The Penn Research Foundation | Porous particles for deep lung delivery |
US20050004049A1 (en) | 1997-03-11 | 2005-01-06 | Elan Pharma International Limited | Novel griseofulvin compositions |
US6024981A (en) | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
US6245760B1 (en) | 1997-05-28 | 2001-06-12 | Aventis Pharmaceuticals Products, Inc | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6887906B1 (en) | 1997-07-01 | 2005-05-03 | Isispharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
ZA9811127B (en) | 1997-12-09 | 2000-07-11 | Lilly Co Eli | Stabilized teriparatide solutions. |
TWI223598B (en) | 1998-06-22 | 2004-11-11 | Pfizer Ireland Pharmaceuticals | An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate |
ITMI981528A1 (it) | 1998-07-03 | 2000-01-03 | Recordati Ind Chimica E Farma | Formulazioni topiche di aciclovir |
FR2781152B1 (fr) | 1998-07-20 | 2001-07-06 | Permatec Tech Ag | Utilisation d'un polymere de type acrylique en tant qu'agent de desagregation |
US20030087820A1 (en) | 1999-01-14 | 2003-05-08 | Young Andrew A. | Novel exendin agonist formulations and methods of administration thereof |
US6495498B2 (en) | 1999-05-27 | 2002-12-17 | Johnson & Johnson Consumer Companies, Inc. | Detergent compositions with enhanced depositing, conditioning and softness capabilities |
US7144574B2 (en) | 1999-08-27 | 2006-12-05 | Maxygen Aps | Interferon β variants and conjugates |
US6316410B1 (en) | 1999-09-22 | 2001-11-13 | National Research Council Of Canada | Parathyroid hormone analogues for the treatment of osteoporosis |
IL150109A0 (en) | 1999-12-09 | 2002-12-01 | Chiron Corp | Method for administering a cytokine to the central nervous system and the lymphatic system |
US20030118547A1 (en) | 2000-01-27 | 2003-06-26 | Vandenberg Grant William | Composition for intestinal delivery |
US6610271B2 (en) | 2000-05-10 | 2003-08-26 | University Of Kentucky Research Foundation | System and method for intranasal administration of lorazepam |
US20040147473A1 (en) | 2000-11-10 | 2004-07-29 | Warrell Raymond P. | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
JP2004526674A (ja) | 2000-12-01 | 2004-09-02 | バテル・メモリアル・インスティテュート | 液体処方物中における生体分子の安定化のための方法 |
US6551578B2 (en) | 2001-02-15 | 2003-04-22 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
US7316819B2 (en) | 2001-03-08 | 2008-01-08 | Unigene Laboratories, Inc. | Oral peptide pharmaceutical dosage form and method of production |
EP2270024B1 (fr) | 2001-06-21 | 2018-10-24 | Ionis Pharmaceuticals, Inc. | Modulation anti-sense d'expression soluble de superoxyde dismutase 1 |
JP2005533775A (ja) | 2002-06-07 | 2005-11-10 | ワラタ ファーマシューティカルズ, インコーポレイテッド | 糖尿病を処置するための組成物および方法 |
US20060106227A1 (en) | 2002-06-13 | 2006-05-18 | Dr Reddy's Laboratories Limited | 3-'2-(Dimethylamino) ethyl!-n-methyl-1h-indole-5-methanesulfonamide and the succinate thereof |
US6855332B2 (en) * | 2002-07-03 | 2005-02-15 | Lyfjathroun Hf. | Absorption promoting agent |
WO2004024125A1 (fr) | 2002-09-16 | 2004-03-25 | Wyeth | Formulations a action retardee pour l'administration par voie orale d'un agent therapeutique polypeptidique et methodes d'utilisation |
GB0226076D0 (en) | 2002-11-08 | 2002-12-18 | Rp Scherer Technologies Inc | Improved formulations containing substituted imidazole derivatives |
US7166575B2 (en) | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
WO2004093917A2 (fr) * | 2003-04-22 | 2004-11-04 | Nastech Pharmaceutical Company Inc. | Administration de triptans par voie intranasale |
US20040258663A1 (en) | 2003-05-08 | 2004-12-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of interferon alpha |
WO2005000222A2 (fr) | 2003-05-30 | 2005-01-06 | Amylin Pharmaceuticals, Inc. | Nouveaux procedes et nouvelles compositions pour une administration amelioree par voie muqueuse de peptides et de proteines |
EP1544209A1 (fr) | 2003-12-15 | 2005-06-22 | M-Phasys GmbH | Protéine de la membrane repliée dans une forme monodisperse |
US20060074025A1 (en) | 2003-12-26 | 2006-04-06 | Nastech Pharmaceutical Company Inc. | Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability |
DE102004017934A1 (de) | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
AU2005247369A1 (en) | 2004-05-10 | 2005-12-08 | Mdrna, Inc. | Compositions and methods for enhanced mucosal delivery of parathyroid hormone |
US9114069B2 (en) | 2004-08-25 | 2015-08-25 | Aegis Therapeutics, Llc | Antibacterial compositions for drug administration |
US20060046969A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Antibacterial compositions for drug administration |
US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
US20090047347A1 (en) | 2005-07-29 | 2009-02-19 | Aegis Therapeutics, Inc. | Compositions for Drug Administration |
ES2458991T3 (es) | 2004-11-12 | 2014-05-07 | Novo Nordisk A/S | Formulaciones estables de péptidos insulinotrópicos |
TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
US7390788B2 (en) | 2005-06-23 | 2008-06-24 | Pert Candace B | Peptide pharmaceutical compositions |
US20090326193A1 (en) | 2006-06-23 | 2009-12-31 | Aegis Therapeutics Llc | Stabilizing alkylglycoside compositions and methods thereof |
US7425542B2 (en) | 2006-06-23 | 2008-09-16 | Aegis Therapeutics, Inc. | Stabilizing alkylglycoside compositions and methods thereof |
US8084022B2 (en) | 2006-06-23 | 2011-12-27 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
US7998927B2 (en) | 2006-06-23 | 2011-08-16 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
AU2008302178B2 (en) * | 2007-09-21 | 2012-01-12 | Saint-Gobain Abrasifs | Melamine methylol for abrasive products |
-
2008
- 2008-12-22 US US12/341,696 patent/US8268791B2/en active Active
-
2009
- 2009-12-22 JP JP2011542586A patent/JP5752048B2/ja active Active
- 2009-12-22 CA CA2748268A patent/CA2748268C/fr active Active
- 2009-12-22 EP EP09835809.6A patent/EP2381773B1/fr active Active
- 2009-12-22 ES ES09835809.6T patent/ES2667248T3/es active Active
- 2009-12-22 DK DK09835809.6T patent/DK2381773T3/en active
- 2009-12-22 KR KR1020117017361A patent/KR101719008B1/ko active IP Right Grant
- 2009-12-22 RU RU2011130526/15A patent/RU2554814C2/ru active
- 2009-12-22 CN CN200980157305.0A patent/CN102325450B/zh active Active
- 2009-12-22 WO PCT/US2009/069326 patent/WO2010075465A1/fr active Application Filing
- 2009-12-22 NZ NZ593782A patent/NZ593782A/xx unknown
- 2009-12-22 MX MX2011006790A patent/MX356271B/es active IP Right Grant
- 2009-12-22 BR BRPI0923403-9A patent/BRPI0923403B1/pt active IP Right Grant
- 2009-12-22 AU AU2009329952A patent/AU2009329952B2/en active Active
-
2012
- 2012-05-23 HK HK12105031.6A patent/HK1164059A1/xx unknown
-
2015
- 2015-01-30 JP JP2015016547A patent/JP2015108008A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070059254A1 (en) | 2003-08-21 | 2007-03-15 | Transoral Pharmaceuticals, Inc. | Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof |
US20060045868A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
Non-Patent Citations (1)
Title |
---|
Pharmazie, 2005, 60, 347-349. |
Also Published As
Publication number | Publication date |
---|---|
CN102325450A (zh) | 2012-01-18 |
DK2381773T3 (en) | 2018-05-28 |
CA2748268C (fr) | 2018-05-15 |
AU2009329952A1 (en) | 2011-07-21 |
HK1164059A1 (en) | 2012-09-21 |
ES2667248T3 (es) | 2018-05-10 |
JP2012513412A (ja) | 2012-06-14 |
JP2015108008A (ja) | 2015-06-11 |
JP5752048B2 (ja) | 2015-07-22 |
MX356271B (es) | 2018-05-21 |
US8268791B2 (en) | 2012-09-18 |
EP2381773B1 (fr) | 2018-02-14 |
BRPI0923403A2 (pt) | 2020-08-11 |
US20090163447A1 (en) | 2009-06-25 |
BRPI0923403B1 (pt) | 2022-02-08 |
CA2748268A1 (fr) | 2010-07-01 |
AU2009329952B2 (en) | 2014-01-09 |
CN102325450B (zh) | 2015-06-17 |
EP2381773A4 (fr) | 2012-12-12 |
RU2554814C2 (ru) | 2015-06-27 |
EP2381773A1 (fr) | 2011-11-02 |
MX2011006790A (es) | 2011-09-27 |
NZ593782A (en) | 2012-11-30 |
RU2011130526A (ru) | 2013-01-27 |
KR20110099049A (ko) | 2011-09-05 |
WO2010075465A1 (fr) | 2010-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101719008B1 (ko) | 약물 투여용 조성물 | |
US20210121573A1 (en) | Absorption enhancers for drug administration | |
US9283280B2 (en) | Compositions for drug administration | |
US11173209B2 (en) | Compositions for drug administration | |
US20110257096A1 (en) | Compositions for drug administration | |
US20090047347A1 (en) | Compositions for Drug Administration | |
US8642564B2 (en) | Compositions for drug administration | |
US20060045868A1 (en) | Absorption enhancers for drug administration | |
US20060046962A1 (en) | Absorption enhancers for drug administration | |
WO2015095389A1 (fr) | Compositions pour administration de médicaments | |
US20120021980A1 (en) | Compositions for drug administration | |
US20180000942A1 (en) | Compositions for drug administration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
GRNT | Written decision to grant |